INTRODUCTION
Diabetes mellitus (DM) is a chronic disease caused by deficient production of insulin by the pancreas and by resistance to insulin's effects, or in some cases both. According to the World Health Organization, more than 422 million people worldwide have diabetes and the number is expected to rise to almost double by 2030. 1 Furthermore, hyperglycemia is the major risk factor responsible for the broad range of complications that are the main cause of mortality and morbidity in people with DM. There are two forms of complications: acute and chronic, including nephropathy, neuropathy and retinopathy. 2 Various biochemical pathways have been proposed to explain the pathological mechanisms of diabetic complications. These include increased polyol pathway flux, activation of the protein kinase C pathway, oxidative stress, and accelerated advanced glycation end-product formation. 2, 3 Aldose reductase (AR) (AR; ALR2; EC 1.1.1.21) is the first enzyme in the polyol pathway and reduces glucose to sorbitol in the presence of nicotinamide adenine dinucleotide phosphate (NADPH). Sorbitol dehydrogenase, the second enzyme in the polyol pathway, oxidizes the intermediate sorbitol to fructose with NAD + as cofactor ( Figure 1 ). 4, 5 It has been reported that AR enzyme activity increases in diabetes. 6 Total glucose utilization by AR-catalyzed reduction is less than 3% under normoglycemia (5.5 mM), whereas the rate is more than 30% under hyperglycemia (20 mM). 6 Increased AR activity has been implicated in the pathogenesis of diabetic complications. 6, 7 Activated AR leads to cell damage through several mechanisms, including accumulation of sorbitol, 8, 9 NADPH depletion, 10, 11 increased NADH/NAD + ratio, 12 and increased fructose levels. 13 Inhibitors of AR thus seem to have the potential to prevent or treat diabetic complications. Even though a wide number of AR inhibitors (ARIs) have been obtained over the last 30 years, the clinical efficacy of these compounds is not completely satisfactory and several of them have shown undesirable side effects. 14 Sorbinil, tolrestat, zopolrestat and ponalrestat were withdrawn from clinical trials because of their side effects. 15 Various thiazolidinedione derivatives are a newer class of antidiabetic drugs [16] [17] [18] [19] [20] that improve glycemic control in type 2 diabetes by increasing insulin action in skeletal muscles, the liver, and adipose tissue. 21, 22 There has been considerable interest in the chemistry of 4-thiazolidinone ring systems, which are a core structure in various synthetic pharmaceuticals displaying a broad spectrum of biological activities such as antidiabetic, As a continuation of our previous studies on 4-thiazolidinone derivatives with ARIs [37] [38] [39] [40] [41] [42] [43] or different biological activities, [44] [45] [46] [47] [48] we report the synthesis of some novel imidazo[2,1-b]thiazole derivatives incorporating two known bioactive nuclei such as hydrazinecarbothioamide or 4-thiazolidinone.
EXPERIMENTAL

Chemical methods
Melting points were determined using a Büchi B-540 melting point apparatus in open capillary tubes and are uncorrected. Elemental analyses were performed on a Thermo Finnigan Flash EA 1112 elemental analyzer. IR spectra were recorded on KBr discs, using a Shimadzu IR Affinity-1 FT-IR spectrophotometer. C-NMR (APT) spectra were measured on a Varian UNITY INOVA (500 MHz) spectrometer using dimethyl sulfoxide (DMSO)-d 6 . The starting materials were either commercially available or synthesized according to the references cited.
General procedure for the synthesis of 2-[[6-(4-bromophenyl) imidazo[2,1-b]thiazol-3-yl]acetyl]-N-cycloalkyl/aralkyl/ arylhydrazinecarbothioamides (3a-f)
To a solution of 2-[6-(4-bromophenyl)imidazo[2,1-b]thiazole-3-yl]acetohydrazide (2) (0.005 mol) in ethanol (30 mL) was added the appropriate isothiocyanate (0.005 mol). The resulting mixture was heated under reflux for 3 h. After cooling, the precipitate was separated and purified by washing with hot ethanol. [6-(4-bromophenyl) imidazo [2,1-b] [6-(4-bromophenyl) imidazo [2,1-b] [6-(4-bromophenyl) imidazo [2,1-b] 
2-[
2-[[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]acetyl]-Nbenzoylhydrazinecarbothioamide (3d)
Yield
2-[[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]acetyl]-N-(4-fluorophenyl)hydrazinecarbothioamide (3e)
2-[[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]acetyl]-N-(4-methoxyphenyl)hydrazinecarbothioamide (3f)
General procedure for the synthesis of 3-cycloalkyl/aralkyl/ aryl-2-[((6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl)acetyl) hydrazono]-5-nonsubstituted/methyl-4-thiazolidinones (4a-j)
absolute ethanol (30 mL) were added anhydrous sodium acetate (0.02 mol) and ethyl bromoacetate/ethyl 2-bromopropionate (0.005 mol). The reaction mixture was refluxed for 20 h, then cooled, diluted with water, and allowed to stand overnight. The crystals were filtered, dried, and purified by crystallization from ethanol or ethanol/water. 
3-Benzyl-2-[((6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl) acetyl)hydrazono]-4-thiazolidinone (4a)
3-Phenethyl-2-[((6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-4-thiazolidinone (4b)
3-Benzoyl-2-[((6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl) acetyl)hydrazono]-4-thiazolidinone (4c)
3-(4-Fluorophenyl)-2-[((6-(4-bromophenyl)imidazo[2,1-b] thiazol-3-yl)acetyl)hydrazono]-4-thiazolidinone (4d)
3-(4-Methoxyphenyl)-2-[((6-(4-bromophenyl)imidazo[2,1-b] thiazol-3-yl)acetyl)hydrazono]-4-thiazolidinone (4e)
3-Benzyl-2-[((6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl) acetyl)hydrazono]-5-methyl-4-thiazolidinone (4f)
3-Phenethyl-2-[((6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl)acetyl)hydrazono]-5-methyl-4-thiazolidinone (4g)
3-Benzoyl-2-[((6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl) acetyl)hydrazono]-5-methyl-4-thiazolidinone (4h)
3-(4-Fluorophenyl)-2-[((6-(4-bromophenyl)imidazo[2,1-b] thiazol-3-yl)acetyl)hydrazono]-5-methyl-4-thiazolidinone (4i)
3-(4-Methoxyphenyl)-2-[((6-(4-bromophenyl)imidazo[2,1-b] thiazol-3-yl)acetyl)hydrazono]-5-methyl-4-thiazolidinone (4j)
Biological methods
Isolation of aldose reductase enzyme
Kidneys obtained from Wistar albino rats were thawed on ice and homogenized with 3 volumes of distilled water. The homogenate were centrifuged at 10,000 × g for 20 min. Saturated ammonium sulfate was added to the supernatant for 40% saturation. The thick suspension was stirred for 15 min and then centrifuged at 10,000 × g for 20 min. The inert protein left in the supernatant was removed by increasing the ammonium sulfate concentration to 50% saturation followed by centrifuging the mixture at 10,000 × g for 20 min. The AR enzyme was precipitated from the 50% saturated solution by adding powdered ammonium sulfate to 75% saturation and was recovered by centrifugation at 10,000 × g for 20 min. 49 Protein concentration was measured as described by Bradford 50 using bovine serum albumin as a standard. The protein concentration was 5.13±0.09 mg/mL.
Determination of aldose reductase activity
AR activity of the freshly prepared supernatant was assayed spectrophotometrically by determining the decrease in NADPH concentration at 340 nm by a UV-1700 Visible spectrophotometer. DL-glyceraldehyde was used as a substrate. The IR spectra of 3a-f displayed bands at about 3296-3118 and 1674-1645 cm -1 associated with the N-H and C=O functions. Absorption bands at 1236-1163 cm -1 , which were attributed to the C=S stretching vibrations, were observed in the IR spectra of compounds 3a-f. The three 1 H-NMR resonances located in the region of 12.55-7.66 ppm were assigned to the NH protons of the hydrazinecarbothioamides and supported the structures of 3a-f. 53 New C=O bands (1757-1712 cm -1 ) in the IR spectra of 4-thiazolidinones (4a-j) provided confirmatory evidence for ring closure. 54 1 H-NMR and 13 C-NMR data were also in agreement with the formation of a 4-thiazolidinone ring. NH signals of 4b-d and 4f-j appeared at δ 11.52-10.54 ppm. In the 1 H NMR spectra of compounds 4f-j, CH-CH 3 protons appeared as a double quartet (1H) at δ 4.54-4.33 and δ 4.50-4.27 ppm and CH-CH 3 protons appeared as a double doublet (3H) at δ 1.63-1.44 and δ 1.56-1.36 ppm, indicating the presence of two isomers in unequal proportions in DMSO-d 6 . This may be explained on the basis of the difference in the relative stability of the E and Z isomers formed due to the rotational restriction about the exocyclic N=C bond at position 2 of the 4-thiazolidinone ring. 54 In the 13 C-NMR (APT) spectra of 3f, 4e, and 4j chosen as prototypes, all the carbons resonated in the expected regions. 55 For example, the protons resonated at δ 30.75, δ 152.44, and δ 169.23 ppm in the The in vitro ARI activity of the synthesized compounds is listed in Table 1 . The enzyme activity was assayed by spectrophotometrically monitoring the NADPH oxidation that accompanies the reduction of DL -glyceraldehyde, which is used as substrate. The inhibition study was performed merely by using a 10 -4 M concentration of each drug. Depending upon the results the best ARI effect was found at the rate of 25.41% in compound 3d. Among these inhibitors, in compound 3c, which is the phenethyl substituted compound, 14.03% inhibition was observed, while in compounds 3e and 3f, which are 4-fluorophenyl and 4-methoxyphenyl substituted compounds, 21.31% and 13.73% inhibition were observed, respectively (Table 1) . Compound 4g, derived from compound 4b as a result of methylation of the nitrogen atom on the thiazolidinone ring, showed 8.22% inhibition, while compound 4h, obtained from compound 4c by methylation of the nitrogen atom on the thiazolidinone ring, showed 5.93% inhibition (Table 1) . Compounds 4i and 4j, obtained by methylation of compounds 4d and 4e, showed 9.31% and 1.42% inhibition, respectively. According to these results, 5-nonsubstituted thiazolidinone derivatives (4a-e) did not show inhibition but 5-methyl Scheme 1. Synthesis of title compounds 3a-f and 4a-j substituted thiazolidinone derivatives (4g-j) showed significant inhibition in the range 1.42-9.31%. A positive influence was exerted by 5-methyl substitution at the thiazolidinone ring on activity. The most efficient compounds were hydrazinecarbothioamide derivatives (3c-f) with 25.41-13.73% (Table 1) .
CONCLUSION
ARIs are one of quite a few types of drugs that have shown prevention of diabetic complications. It is still a challenge to develop a drug candidate molecule. We report the synthesis and ARI activity effects of hydrazinecarbothioamides (3a-f) and 4-thiazolidinones (4a-j) bearing an imidazo [2,1-b] thiazole moiety. On the basis of our preliminary ARI screening results on imidazo[2,1-b]thiazole derivatives, we embarked on the synthesis of more derivatives to discover more active molecules.
